Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PHGE
PHGE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PHGE News
BiomX Shares Surge Following 19.99% Stake Acquisition
Jan 27 2026
Benzinga
Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
Jan 27 2026
Benzinga
BiomX Secures $3 Million in Private Placement to Advance Phage Programs
Dec 29 2025
Globenewswire
BiomX Secures $3 Million in Private Placement to Advance Phage Programs
Dec 29 2025
Newsfilter
BiomX Suspends Phase 2b Trial of BX004 for Cystic Fibrosis Due to Elevated Adverse Event Rates
Dec 09 2025
NASDAQ.COM
Crude Oil Declines by More Than 1%; Structure Therapeutics Stock Soars
Dec 08 2025
Benzinga
US Stocks Show Mixed Performance; Dow Drops More Than 100 Points
Dec 08 2025
Benzinga
HC Wainwright & Co. Confirms Buy Rating for BiomX (PHGE)
Nov 27 2025
NASDAQ.COM
BiomX Seeks FDA Approval to Resume Cystic Fibrosis Trial Following Nebulizer Device Evaluation
Nov 26 2025
Benzinga
BiomX to Proceed with Cystic Fibrosis Research Using Updated BX004 Dosing; Results Anticipated in Q2 2026
Nov 26 2025
NASDAQ.COM
Autodesk Shares Rise Approximately 6%; 20 Stocks Making Moves in Premarket Trading
Nov 26 2025
Benzinga
BiomX Updates BX004 Clinical Trial Progress, Expects Q2 2026 Results
Nov 25 2025
Newsfilter
Stock Splits Scheduled for This Week (November 24 to November 28) – Keep Your Investments Active
Nov 23 2025
TipRanks
BiomX Shares Program Update and Reveals New FDA Insights That May Broaden BX004 Development Options
Oct 17 2025
Newsfilter
HC Wainwright & Co. Affirms Buy Rating for BiomX, Keeps $15 Price Target Intact
Aug 20 2025
Benzinga
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
Aug 13 2025
Newsfilter
Show More News
